Progesterone: the ultimate endometrial tumor suppressor.
about
Metformin for endometrial hyperplasiaThe estrogen receptor joins other cancer biomarkers as a predictor of outcomePast, present, and future of hormonal therapy in recurrent endometrial cancerEndometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasRole of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer developmentDirect effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysisSystematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancerProgesterone action in breast, uterine, and ovarian cancers.miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer.Classifying ten types of major cancers based on reverse phase protein array profiles.Influence of AKT on progesterone action in endometrial diseases.Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.An immunohistochemical study on the expression of sex steroid receptors, Ki-67 and cytokeratins 7 and 20 in feline endometrial adenocarcinomas.Determination of Heavy Metal Concentrations in Normal and Pathological Human Endometrial Biopsies and In Vitro Regulation of Gene Expression by Metals in the Ishikawa and Hec-1b Endometrial Cell Line.Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.Metformin for endometrial hyperplasia: a Cochrane protocolNeonatal Progesterone Programs Adult Uterine Responses to Progesterone and Susceptibility to Uterine DysfunctionPromising clinical practices of metformin in women with PCOS and early-stage endometrial cancer.Altered expression of microRNA-451 in eutopic endometrium of baboons (Papio anubis) with endometriosis.Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation.Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.Estrogen receptors and human disease: an update.Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesFluorescent ligand for human progesterone receptor imaging in live cells.Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cellsProgesterone signaling inhibits cervical carcinogenesis in miceContinuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growthProgesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma.PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma.Changes of The Uterine Tissue in Rats with Polycystic Ovary Syndrome Induced by Estradiol Valerate.Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer.Epigenetic modification restores functional PR expression in endometrial cancer cells.Factors predicting recurrent endometrial cancer.
P2860
Q26472029-955C0697-B274-4A1A-851E-CDB1ECF4F746Q26865554-3FBAD929-21F4-4A47-AA6B-06E9DC93BF84Q26993208-C8C88CEE-9775-477F-817E-1DE532F7569AQ28074769-D3B97CA5-3B26-4700-BC4C-BE3ABFD1645EQ28509811-E371798D-5E45-4E35-8FEC-238B96EDB7F7Q33675285-0B392739-04EF-498C-AD76-3B1C8EB0A9C5Q34321877-C1546EEC-5A6C-4E98-9AC9-D24D8FE0439FQ34501893-28CBFC5C-C65A-4D2C-9C46-849AB494E49AQ34654640-5216E2DC-4EA1-437F-B589-848969F0DC25Q35108906-5465C492-D0B5-454C-A0C6-A0A44C2B1B81Q35555424-B706EAF7-4ADF-4699-9FC5-F907BB3A7ACEQ35590038-9FC3A799-2014-4C67-B0C1-7C4BC77E573DQ35617565-9788B9B6-5898-483B-8A5B-B97ECDE932D1Q35663624-10C7C6BF-57C6-4452-8EE7-182773AF96C6Q35744464-7FB1C18D-EC03-43BC-B01F-BD6EAE33F359Q35850962-988F59C2-E788-40EF-825F-DDB2A2C9DD53Q35879733-61AB33CB-5D66-4262-B36C-9D7E931746FDQ35918161-D735292B-9DE9-4B70-B89C-5B7C34E544EEQ35945498-23437B3D-4715-4817-88F9-B1E35CB151FDQ36105494-A41875A7-1AF7-4988-A0F1-880D12C815C7Q36107514-A536C5C3-C736-44A1-89BA-87A40A957331Q36250770-8118C48B-3757-4565-A579-F77F322B994CQ36276318-F6FADD2D-5023-49DB-9038-9145953FC18FQ36298532-E1DB861A-BCB5-4BE2-B545-EE2640262DCEQ36466930-27255C0B-E66B-4552-9F16-7E21CBE6EBC5Q36475922-CD3A2D84-4FF2-4803-BE5D-C41DDC1C3468Q36661810-3EC5F190-CBBE-4EB4-83A8-459CBB3B0409Q36669005-41C778C9-B26C-4875-8481-2334D664BA39Q36857601-CA077230-0634-4C4E-9CDD-751E51A77AD6Q37016586-F16A79AF-9589-4462-A327-C1CCE7BA9C38Q37273132-E165FD7E-0BE8-421F-BCE4-82C9A0D6D352Q37275914-0E0B2182-CDA4-4034-9C1C-7A27BF8A77F4Q37353846-2C54DFAE-9EFD-4616-BC9A-C788A7BADB15Q37393019-7437C73C-0C92-4114-B046-628A574313DAQ37406760-86475638-9F7C-4E6D-B3CA-C915CA075C36Q37516309-FCB5E72F-2512-46EB-AC49-593754A59B80Q37561758-AD860D90-454E-40C9-A808-D46589417567Q37661580-B029D3EE-E43F-4AF6-9F6D-15A3800C97F3Q37671692-014A2500-5B46-4AF3-B006-1B6ED92CFBBAQ37703894-F4444401-B150-40BE-9E65-E1DF915F3926
P2860
Progesterone: the ultimate endometrial tumor suppressor.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Progesterone: the ultimate endometrial tumor suppressor.
@ast
Progesterone: the ultimate endometrial tumor suppressor.
@en
type
label
Progesterone: the ultimate endometrial tumor suppressor.
@ast
Progesterone: the ultimate endometrial tumor suppressor.
@en
prefLabel
Progesterone: the ultimate endometrial tumor suppressor.
@ast
Progesterone: the ultimate endometrial tumor suppressor.
@en
P2860
P1476
Progesterone: the ultimate endometrial tumor suppressor
@en
P2093
Kristina W Thiel
P2860
P304
P356
10.1016/J.TEM.2011.01.005
P577
2011-02-25T00:00:00Z